News

News 2017-11-19T23:06:00+00:00

Annual Results 2017

LONDON, 23 April 2018: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience”, “Arix” or the “Company”), a global life sciences company supporting medical innovation, today announces its annual results for the year ended 31 December 2017. Highlights within the period Successful IPO on the Main Market of the London Stock Exchange in February 2017, raising £112 million Acquired direct interests in 8 new Arix Group Businesses, bringing the total [...]

April 23rd, 2018|

Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018

LONDON, 5 April 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, announces that Joe Anderson, CEO, will present at the H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018, at 11.30 CEST at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. A webcast of the presentation will be accessible live [...]

April 5th, 2018|

Arix Bioscience plc notes Verona Pharma plc report of positive top-line data from Phase 2b Clinical trial of RPL554 for maintenance treatment of COPD

LONDON, 26 March 2018: Arix Bioscience plc (LSE: ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, is pleased to note the positive data reported by one of its Group Businesses, Verona Pharma, from  the Phase 2b Clinical Trial of RPL554  for Maintenance Treatment of COPD. Commenting on the news, Joe Anderson, CEO of Arix Bioscience, said: “We are pleased to note [...]

March 26th, 2018|

Former Chief Operating Officer of Kite Pharma, Cynthia M. Butitta, appointed to Autolus’ Board of Directors

London, 12 March 2018 – Autolus Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced the appointment of Cynthia M. Butitta to its board of directors, effective immediately. Ms. Butitta is a highly experienced biopharma executive who most recently played an instrumental role in building Kite Pharma, Inc. from January 2014 until its acquisition by Gilead [...]

March 12th, 2018|

Autolus announces confidential submission of draft registration statement for potential initial public offering in the United States

Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its Group Business Autolus Limited has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of ordinary shares in the United States. The timing and the terms of this potential initial public offering [...]

March 6th, 2018|

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

LONDON, PARIS 21 FEBRUARY 2018: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance [...]

February 21st, 2018|

Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients

LONDON, HONG KONG  19 FEBRUARY 2018: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company building and financing innovative young medical businesses and Fosun International Limited (00656:HK) (“Fosun”), jointly announce a strategic agreement to develop and commercialise new clinical therapies for patients. As part of the agreement, Arix and Fosun will collaborate to invest in and create new [...]

February 19th, 2018|

CEO Letter to Shareholders

LONDON, 4 January 2018:  As 2018 gets underway, I would like to reflect on Arix Bioscience plc’s (LSE: ARIX) (“Arix Bioscience” or “Arix”) first year as a public company and offer some thoughts on the year ahead.  We started 2017 with the ambition of building a business with the capital, the skills and the experience to take breakthroughs in life sciences and accelerate their development [...]

January 4th, 2018|

Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma

- APRIL CAR-T cells concurrently target BCMA and TACI to reduce the risk of antigen negative disease relapse - London, 2 January 2018 – Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of pre-clinical data from a novel, dual-targeted, proliferating-inducing ligand (APRIL) Chimeric Antigen Receptor (CAR) in Blood, the journal of the [...]

January 2nd, 2018|

Arix Bioscience co-leads $30 million financing for Aura Biosciences

Funding to advance development of Aura’s novel treatment to selectively destroy cancer cells; lead candidate AU-011 currently in Phase 1b/2 study to treat ocular melanoma, an orphan indication LONDON, 21 December 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”), a global healthcare and life science company supporting medical innovation, today announces that it has co-led a $30 million Series C financing round for Aura Biosciences [...]

December 21st, 2017|